Anat Binur, Ph.D. is CEO and Co-Founder at Ukko, where she's leading an effort to engineer the proteins that induce immune response in people who suffer from food allergies. The effort at Ukko is deeply rooted in computational biology. The company leverages artificial intelligence to analyze proteins taken directly from patients' blood in an effort to determine the specific attributes of the proteins that trigger immune response. Then, it applies a unique combination of compute power and biology to identify and understand the changes it wants to engineer and predict the best possible designs. Learn how Ukko is fostering a culture of IT and biology collaboration and what lured this dynamic entrepreneur into biopharma on this episode of the Business of Biotech.